PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 78 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2014. The put-call ratio across all filers is 0.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $27,817,000 | +53.7% | 3,219,577 | +12.6% | 0.01% | +25.0% |
Q3 2016 | $18,098,000 | +57.7% | 2,859,154 | +5.1% | 0.00% | +33.3% |
Q2 2016 | $11,477,000 | -3.4% | 2,719,685 | -0.2% | 0.00% | 0.0% |
Q1 2016 | $11,884,000 | -28.3% | 2,725,796 | +0.8% | 0.00% | -25.0% |
Q4 2015 | $16,580,000 | +2.1% | 2,704,794 | -4.8% | 0.00% | 0.0% |
Q3 2015 | $16,245,000 | -20.5% | 2,840,096 | +3.6% | 0.00% | -20.0% |
Q2 2015 | $20,442,000 | +22.4% | 2,740,154 | -1.9% | 0.01% | +25.0% |
Q1 2015 | $16,705,000 | -19.5% | 2,793,406 | +1.8% | 0.00% | -20.0% |
Q4 2014 | $20,753,000 | +58.9% | 2,745,169 | +9.1% | 0.01% | +25.0% |
Q3 2014 | $13,063,000 | +16.8% | 2,516,967 | -3.0% | 0.00% | +33.3% |
Q2 2014 | $11,184,000 | -1.0% | 2,594,840 | -6.0% | 0.00% | 0.0% |
Q1 2014 | $11,294,000 | -9.2% | 2,761,329 | +18.4% | 0.00% | -25.0% |
Q4 2013 | $12,435,000 | +4.4% | 2,332,965 | -1.7% | 0.00% | 0.0% |
Q3 2013 | $11,915,000 | +54.5% | 2,373,556 | +37.3% | 0.00% | +33.3% |
Q2 2013 | $7,711,000 | – | 1,729,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
SEARLE & CO. | 60,000 | $349,000 | 0.34% |
TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |